ClinicalTrials.gg
CompletedNCT00213148Updated Jul 17, 2018Results posted

Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

A Phase 2 interventional study of Anastrozole 1 mg and Anastrozole 5 mg in Anovulation, sponsored by EMD Serono. Completed at 1 site in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-07-17.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2005, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
271
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing clomiphene in Anovulation — none open to participants now, 1 under way, 1 of them phase 3. Clomiphene · Anovulation.

Enrollment
3rd of 15
271 · median 159
Started
2005
the only one that year
Phase 2
2 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
1 of 15
EMD Serono

Among the 15 studies testing clomiphene in Anovulation, this one is the 3rd largest by enrollment, is the only one that started in 2005, is one of 2 in phase 2, and was the 1st registered.

Anovulation

76 studies on the registry are indexed under Anovulation; 7 are open to participants now.

Browse Anovulation studies →

Open to participants now

None of the 15 studies testing clomiphene in Anovulation is open now. The open studies under Anovulation, anywhere →

About clomiphene

Clomiphene: first FDA approval 1967 (CLOMID). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Anovulation studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing clomiphene in Anovulation as a file.
02

Study summary

The purpose of this study is to investigate and compare the safety and efficacy of various doses of the aromatase inhibitor (anastrozole) versus clomiphene citrate in stimulating follicular growth and ovulation in infertile women with ovulatory dysfunction.

03

Conditions studied

  • Anovulation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-40 years
  • Ovulatory dysfunction characterized by irregular and/or extended cycles
  • Non-smoker

Exclusion criteria

Exclusion Criteria:

  • No previous gonadotropin treatment
  • No more than 6 previous clomiphene treatment cycles
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
271 participants (actual)

Study arms

  • Active comparator
    Clomiphene Citrate 50 Milligram (mg)

    Drug: Clomiphene Citrate 50 mg

  • Active comparator
    Clomiphene Citrate 100 mg

    Drug: Clomiphene Citrate 100 mg

  • Experimental
    Anastrozole 1 mg

    Drug: Anastrozole 1 mg

  • Experimental
    Anastrozole 5 mg

    Drug: Anastrozole 5 mg

  • Experimental
    Anastrozole 10 mg

    Drug: Anastrozole 10 mg

Interventions

  • Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).

  • Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).

  • Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).

  • Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).

  • Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).

06

What researchers measure

Primary outcomes

  1. Ovulation Rate in Cycle 1

    Ovulation rate was defined as the percentage of subjects who ovulated (mid-luteal Progesteron \[P4\] level greater than or equal to \[\>=\] 10 nanogram per milliliter \[ng/mL\] and/or pregnancy).

    Time frame: Up to 1 month

Secondary outcomes

  1. Number of Subjects With Clinical Pregnancy in Cycle 1

    Clinical pregnancy was defined as the existence of at least one ultrasonographically confirmed gestational sac in the uterus with fetal heart activity.

    Time frame: Up to 1 month

07

Results

Posted Jul 17, 2018

Participant flow

Cycle 1 (1 Month)
Participant flow — Cycle 1 (1 Month)
MilestoneClomiphene Citrate 50 Milligram (mg)Clomiphene Citrate 100 mgAnastrozole 1 mgAnastrozole 5 mgAnastrozole 10 mg
Started770797639
Completed530605817
Not completed240191822
Withdrew: Lost to follow-up10221
Withdrew: Adverse event00100
Withdrew: Lack of efficacy40858
Withdrew: Protocol violation10100
Withdrew: Other30227
Withdrew: Pregnancy unrelated to therapy00010
Withdrew: Non resolving cyst > 25mm00001
Withdrew: Discontinued before start of cycle 2150585
Cycle 2 (1 Month)
Participant flow — Cycle 2 (1 Month)
MilestoneClomiphene Citrate 50 Milligram (mg)Clomiphene Citrate 100 mgAnastrozole 1 mgAnastrozole 5 mgAnastrozole 10 mg
Started4310425241
Completed294283311
Not completed146141930
Withdrew: Lost to follow-up00221
Withdrew: Lack of efficacy137616
Withdrew: Other21287
Withdrew: Pregnancy unrelated to therapy01000
Withdrew: Non resolving cyst > 25mm10000
Withdrew: Discontinued before start of cycle 3101336
Cycle 3 (1 Month)
Participant flow — Cycle 3 (1 Month)
MilestoneClomiphene Citrate 50 Milligram (mg)Clomiphene Citrate 100 mgAnastrozole 1 mgAnastrozole 5 mgAnastrozole 10 mg
Started2310262422
Completed238252321
Not completed02111
Withdrew: Lost to follow-up02001
Withdrew: Other00110

Outcome measures

PrimaryOvulation Rate in Cycle 1

Ovulation rate was defined as the percentage of subjects who ovulated (mid-luteal Progesteron \[P4\] level greater than or equal to \[\>=\] 10 nanogram per milliliter \[ng/mL\] and/or pregnancy).

Time frame:
Up to 1 month
Reported as:
Number · percentage of subjects
Ovulation Rate in Cycle 1
percentage of subjectsClomiphene Citrate 50 mgAnastrozole 1 mgAnastrozole 5 mgAnastrozole 10 mg
Ovulation Rate in Cycle 164.930.436.835.9
SecondaryNumber of Subjects With Clinical Pregnancy in Cycle 1

Clinical pregnancy was defined as the existence of at least one ultrasonographically confirmed gestational sac in the uterus with fetal heart activity.

Time frame:
Up to 1 month
Reported as:
Number · subjects
Number of Subjects With Clinical Pregnancy in Cycle 1
subjectsClomiphene Citrate 50 mgAnastrozole 1 mgAnastrozole 5 mgAnastrozole 10 mg
Number of Subjects With Clinical Pregnancy in Cycle 110470

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clomiphene Citrate 50 mg (Cycle 1)—1/77 (1.3%)23/77 (29.9%)
Anastrozole 1 mg (Cycle 1)—0/79 (0%)12/79 (15.2%)
Anastrozole 5 mg (Cycle 1)—0/76 (0%)17/76 (22.4%)
Anastrozole 10 mg (Cycle 1)—0/39 (0%)4/39 (10.3%)
Clomiphene Citrate 50 mg (Cycle 2)—0/43 (0%)6/43 (14%)
Clomiphene Citrate 100 mg (Cycle 2)—0/10 (0%)2/10 (20%)
Anastrozole 1 mg (Cycle 2)—0/42 (0%)2/42 (4.8%)
Anastrozole 5 mg (Cycle 2)—0/52 (0%)4/52 (7.7%)
Anastrozole 10 mg (Cycle 2)—0/41 (0%)7/41 (17.1%)
Clomiphene Citrate 50 mg (Cycle 3)—0/23 (0%)4/23 (17.4%)
Clomiphene Citrate 100 mg (Cycle 3)—0/10 (0%)2/10 (20%)
Anastrozole 1 mg (Cycle 3)—0/26 (0%)1/26 (3.8%)
Anastrozole 5 mg (Cycle 3)—0/24 (0%)2/24 (8.3%)
Anastrozole 10 mg (Cycle 3)—0/22 (0%)2/22 (9.1%)
Most frequent serious events
Most frequent serious events
EventClomiphene Citrate 50 mg (Cycle 1)Anastrozole 1 mg (Cycle 1)Anastrozole 5 mg (Cycle 1)Anastrozole 10 mg (Cycle 1)Clomiphene Citrate 50 mg (Cycle 2)Clomiphene Citrate 100 mg (Cycle 2)Anastrozole 1 mg (Cycle 2)Anastrozole 5 mg (Cycle 2)Anastrozole 10 mg (Cycle 2)Clomiphene Citrate 50 mg (Cycle 3)Clomiphene Citrate 100 mg (Cycle 3)Anastrozole 1 mg (Cycle 3)Anastrozole 5 mg (Cycle 3)Anastrozole 10 mg (Cycle 3)
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/770/790/760/390/430/100/420/520/410/230/100/260/240/22
Most frequent other events
Most frequent other events
EventClomiphene Citrate 50 mg (Cycle 1)Anastrozole 1 mg (Cycle 1)Anastrozole 5 mg (Cycle 1)Anastrozole 10 mg (Cycle 1)Clomiphene Citrate 50 mg (Cycle 2)Clomiphene Citrate 100 mg (Cycle 2)Anastrozole 1 mg (Cycle 2)Anastrozole 5 mg (Cycle 2)Anastrozole 10 mg (Cycle 2)Clomiphene Citrate 50 mg (Cycle 3)Clomiphene Citrate 100 mg (Cycle 3)Anastrozole 1 mg (Cycle 3)Anastrozole 5 mg (Cycle 3)Anastrozole 10 mg (Cycle 3)
HeadacheNervous system disorders9/775/799/762/390/430/101/421/523/412/230/101/261/242/22
Adnexa uteri painReproductive system and breast disorders6/772/794/760/392/431/100/420/521/412/230/100/260/240/22
Hot flushVascular disorders0/770/790/760/393/431/100/422/520/410/231/100/261/240/22
Breast tendernessReproductive system and breast disorders0/770/790/760/390/430/100/420/520/410/231/100/260/240/22
NauseaGastrointestinal disorders4/775/792/762/391/430/101/421/523/410/230/100/260/240/22
Back painMusculoskeletal and connective tissue disorders4/770/792/760/390/430/100/420/520/410/230/100/260/240/22

Baseline characteristics

Age, Continuous
Age, Continuous(years)Clomiphene Citrate 50 mgAnastrozole 1 mgAnastrozole 5 mgAnastrozole 10 mgTotal
Mean29.0 ± 3.928.8 ± 3.929.6 ± 3.929.3 ± 3.429.2 ± 3.8
Sex: Female, Male
Sex: Female, Male(Participants)Clomiphene Citrate 50 mgAnastrozole 1 mgAnastrozole 5 mgAnastrozole 10 mgTotal
Female77797639271
Male00000
08

Study locations

1 site
  • Local US Medical Information
    Rockland, Massachusetts 02370, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2005 to primary completion in Dec 2007, 33 months.

Results were first posted in Jul 2018, 10 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 21, 2005
StartActual
Mar 10, 2005
Primary completionActual
Dec 12, 2007
CompletionActual
Dec 12, 2007
Results first posted
Jul 17, 2018
Last update
Jul 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00213148
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Sep 21, 2005
Start date
Mar 10, 2005
Primary completion
Dec 12, 2007
Completion
Dec 12, 2007
Results posted
Jul 17, 2018
Last update
Jul 17, 2018

Study contacts

Medical Responsible
study director · EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Clomiphene

Start the discussion